Cancer
Conditions
Brief summary
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics.To further study the pharmacokinetic characteristics of Anlotinib in the human body, recommend a reasonable regimen for subsequent research.
Interventions
DRUGAnlotinib
Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Histological documentation of Advanced solid tumors except the digestive tract tumors,at least one measurable lesion (by RECIST1.1) * Lack of the standard treatment or treatment failure * 18-65 years,ECOG PS:0-1,Life expectancy of more than 3 months * 30 Days or more from the last cytotoxic therapy * Main organs function is normal * Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped * Patients should participate in the study voluntarily and sign informed consent
Exclusion criteria
* Patients who are used by anlotinib * Patients with factors that could affect oral medication (such as dysphagia，chronic diarrhea, intestinal obstruction etc.) * Brain metastases patients with symptoms or symptoms controlled \< 3 months * Patients with any severe and/or unable to control diseases，including： 1. Blood pressure unable to be controlled ideally(systolic pressure≥150 mmHg，diastolic pressure≥100 mmHg); 2. Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QT≥480ms) and patients with Grade 1 or higher congestive heart failure (NYHA Classification); 3. Patients with active or unable to control serious infections; 4. Patients with cirrhosis, decompensated liver disease, or active hepatitis; 5. Patients with poorly controlled diabetes (fasting blood glucose(FBG)\>10mmol/L) 6. Urine protein ≥ ++，and 24-hour urinary protein excretion\>1.0 g confirmed * Patients with non-healing wounds or fractures * Patients with any CTC AE Grade 1 or higher bleeding events occurred in the lungs or any CTC AE Grade 2 or higher bleeding events occurred within 4 weeks prior to assignment;Patients with any physical signs of bleeding diathesis or receiving thrombolysis and anticoagulation * Patients with drug abuse history and unable to get rid of or Patients with mental disorders * Patients participated in other anticancer drug clinical trials within 4 weeks * History of immunodeficiency * Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics of Anlotinib (in whole blood):Half life（t1/2） | up to 18 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL) | Half life（t1/2）,t1/2 in h.In the study of single-dose, full PK profiles will be obtained at H0/H1/H2/H4/H8/H11/H24/H48/H72/H120/H168/H240(H mans Hour).In the study of multiple-dose,full PK profiles will be obtained at D1/D4/D7/D10/D14/D18/Before the next cycle(D means Day). |
| Pharmacokinetics of Anlotinib (in whole blood):Peak Plasma Concentration(Cmax) | up to 18 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL) | Peak Plasma Concentration(Cmax),Cmax in ng/mL.In the study of single-dose, full PK profiles will be obtained at H0/H1/H2/H4/H8/H11/H24/H48/H72/H120/H168/H240（H means Hour）.In the study of multiple-dose,full PK profiles will be obtained at D1/D4/D7/D10/D14/D18/Before the next cycle（D means Day）. |
| Pharmacokinetics of Anlotinib (in whole blood):Peak time（Tmax） | up to 18 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL) | Peak time（Tmax）,Tmax in h.In the study of single-dose, full PK profiles will be obtained at H0/H1/H2/H4/H8/H11/H24/H48/H72/H120/H168/H240(H means hour).In the study of multiple-dose,full PK profiles will be obtained at D1/D4/D7/D10/D14/D18/Before the next cycle(D means Day). |
| Cumulative excretion of Anlotinib (in urine) | up to 10 Days(endpoint when the two consecutive time points of cumulative excretion <1%) | — |
| Pharmacokinetics of Anlotinib (in whole blood):Area under the plasma concentration versus time curve (AUC) | up to 18 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL) | Area under the plasma concentration versus time curve (AUC), AUC in ng.h/mL.In the study of single-dose, full PK profiles will be obtained at H0/H1/H2/H4/H8/H11/H24/H48/H72/H120/H168/H240(H means Hour).In the study of multiple-dose,full PK profiles will be obtained at D1/D4/D7/D10/D14/D18/Before the next cycle(D means Day). |
| Pharmacokinetics of Anlotinib (in whole blood):Clearance（CL） | up to 18 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL) | Clearance（CL）,CL in L/h.In the study of single-dose, full PK profiles will be obtained at H0/H1/H2/H4/H8/H11/H24/H48/H72/H120/H168/H240(H means Hour).In the study of multiple-dose,full PK profiles will be obtained at D1/D4/D7/D10/D14/D18/Before the next cycle(D means Day). |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR) | each 42 days up to intolerance the toxicity or PD(Disease progression) (up to 24 months) |
Countries
China
Outcome results
None listed